#23316 скачать в хорошем качестве

#23316

Patient's preference to sacral neuromodulation PERROUIN-VERBE M1, THOMAS L1, HASSINE A1, PROUZA A1, HASHIM H1 1. Bristol Urological institute, Southmead Hospital, Bristol, United Kingdom KEYWORDS: Overactive Bladder, Neuromodulation, Voiding Dysfunction Sacral neuromodulation (SNM) is recommended for the treatment of refractory overactive bladder (OAB) syndrome and non-obstructive urinary retention (1). Prior to 2019, only one device (Medtronic® InterStim™ II) with head-MRI compatibility was available. However since then, three full-body, MRI-compatible SNM devices (Medtronic® InterStim™II recharge-free, Medtronic® InterStim™ Micro rechargeable and Axonics® r-SNM™ rechargeable) with different characteristics have become available thus offering more choice for patients and allowing more patients to have this therapy. The two rechargeable devices provide stimulation thanks to a very small implantable stimulator, and they are tested to deliver the therapy for at least 15 years. Due to the recent introduction of these devices, no study has been carried out to determine which criterion seems to best guide the patient in the choice of treatment. We conducted a quality improvement project to capture the patient preferences regarding choice of SNM device to help develop a patient decision aid.